Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06823167 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
A Phase 1 study of Hematologic Malignancies and Solid Malignancies, sponsored by Immunome.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 117
- Enrollment target
- 10
- Study locations
NCT06823167 is a Phase 1 study of Hematologic Malignancies and Solid Malignancies that is actively recruiting participants, run by Immunome. The registered enrollment target is 117 participants, below the 2,709-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (96% lower). The trial reports 10 study locations across 8 states.
The verdict
NCT06823167, a Phase 1 study of Hematologic Malignancies and Solid Malignancies, is actively recruiting participants, sponsored by Immunome.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 117 participants
- Enrollment target
- 10
- Study locations
Study Summary
IM-1021-101 is a Phase 1 study to determine the safety and effectiveness of IM-1021 in treating participants with advanced cancer.
Conditions Studied
Interventions
- BIOLOGICAL IM-1021
Study Locations (10)
Michigan
- University of Michigan - Ann Arbor
- START Midwest - Grand Rapids
Texas
- MD Anderson Cancer Center - Houston
- NEXT Oncology - Irving
California
- City Of Hope - Duarte
Connecticut
- Yale University Medical Center - New Haven
Georgia
- Emory Winship Cancer Institute - Atlanta
Nebraska
- University of Nebraska Medical Center - Omaha
Ohio
- Gabrail Cancer Center - Canton
Tennessee
- Sarah Cannon Research Institute - Oncology Partners - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2025-02-26 |
| Est. Completion | 2029-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06823167
The ClinicalTrials.gov registry entry for NCT06823167 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,709-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (96% lower). The listed sponsor is Immunome, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hematologic Malignancies appearing as the primary indexed condition, and to 1 intervention - of which IM-1021 is the first listed.
NCT06823167 reports 10 study locations spanning 8 distinct geographic areas - top geographies include Michigan, Texas, California.
Frequently Asked Questions
What is clinical trial NCT06823167 about?
NCT06823167 is a clinical study titled "A Phase 1 Study of IM-1021 in Participants With Advanced Cancer". IM-1021-101 is a Phase 1 study to determine the safety and effectiveness of IM-1021 in treating participants with advanced cancer.
What is the current status of trial NCT06823167?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 117 participants. The study started on 2025-02-26. Estimated completion is 2029-02.
What conditions does trial NCT06823167 study?
This clinical trial studies the following conditions: Hematologic Malignancies, Solid Malignancies.
What interventions are being tested in trial NCT06823167?
The interventions under investigation include: IM-1021 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06823167?
This trial is sponsored by Immunome, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06823167 being conducted?
This trial has 10 study locations across California, Connecticut, Georgia, Michigan, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
RECRUITING · Phase 1
-
Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant
RECRUITING · Phase 1
-
A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies
RECRUITING · Phase 1
-
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RECRUITING · Phase 1
-
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.